

Editor: Daniel Limmer Managing Editor: Matthew J. Hauber Marketing Manager: Anne Smith

Lippincott Williams & Wilkins

22.002

. ۲.

्र

Э

1

do-

1 1 4

7

and the second second

3

CC

ŝ

4

DOCKE

351 West Camden Street Baltimore, Maryland 21201-2436 USA

227 East Washington Square Philadelphia, PA 19106

All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner.

The publisher is not responsible (as a matter of product liability, negligence or otherwise) for any injury resulting from any material contained herein. This publication contains information relating to general principles of medical care which should not be construed as specific instructions for individual patients. Manufacturers' product information and package inserts should be reviewed for current information, including contraindications, dosages and precautions.

Printed in the United States of America

Entered according to Act of Congress, in the year 1885 by Joseph P Remington, in the Office of the Librarian of Congress, at Washington DC

Copyright 1889, 1894, 1905, 1907, 1917, by Joseph P Remington

Copyright 1926, 1936, by the Joseph P Remington Estate

Copyright 1948, 1951, by the Philadelphia College of Pharmacy and Science

Copyright 1956, 1960, 1965, 1970, 1975, 1980, 1985, 1990, 1995, by the Philadelphia <u>College</u> of Pharmacy and Science

Copyright 2000, by the University of the Sciences in Philadelphia

All Rights Reserved Library of Congress Catalog Card Information is available ISBN 0-683-306472

The publishers have made every effort to trace the copyright holders for borrowed material. If they have inadvertently overlooked any, they will be pleased to make the necessary arrangements at the first opportunity.

The use of structural formulas from USAN and the USP Dictionary of Drug Names is by permission of The USP Convention. The Convention is not responsible for any inaccuracy contained herein.

Notice—This text is not intended to represent, nor shall it be interpreted to be, the equivalent of or a substitute for the official United States Pharmacopeia (USP) and/or the National Formulary (NF). In the event of any difference or discrepancy between the current official USP or NF standards of strength, quality, purity, packaging and labeling for drugs and representations of them herein, the context and effect of the official compendia shall prevail.

To purchase additional copies of this book call our customer service department at (800) 638-3030 or fax orders to (301) 824-7390. International customers should call (301) 714-2324.

 $\begin{array}{c} 00 \ 01 \ 02 \ 03 \ 04 \\ 1 \ 2 \ 3 \ 4 \ 5 \ 6 \ 7 \ 8 \ 9 \ 10 \end{array}$

Carl INA ROLL

ST. T. L.

Table of Contents

Part 1 Orientation

1	Scope of Pharmacy
2	Evolution of Pharmacy
3	Ethics and Professionalism
4	The Practice of Community Pharmacy
5	Pharmacists in Industry
6	Pharmacists in Government
7	Pharmacists and Public Health
8	Information Resources in Pharmacy and the
	Pharmaceutical Sciences
9	Clinical Drug Literature
10	Research

DOCKE

R

м

Δ

Part 2 Pharmaceutics

11	Pharmaceutical Calculations
12	Statistics
13	Molecular Structure, Properties, and States of Matter
14	Complex Formation
15	Thermodynamics
16	Solutions and Phase Equilibria
17	Ionic Solutions and Electrolytic Equilibria
18	Tonicity, Osmoticity, Osmolality, and Osmolarity
19	Chemical Kinetics
20	Interfacial Phenomena
21	Colloidal Dispersions
22	Coarse Dispersions
23	Rheology

Part 3 Pharmaceutical Chemistry

the state of the s	350
Inorganic Pharmaceutical Chemistry	004
Organic Pharmaceutical Chemistry	385
Natural Products	409
Drug Nomenclature—United States Adopted	
Names	441
Structure-Activity Relationship and Drug Design	458
Fundamentals of Radionuclides	469
	Inorganic Pharmaceutical Chemistry Organic Pharmaceutical Chemistry Natural Products Drug Nomenclature—United States Adopted Names Structure-Activity Relationship and Drug Design Fundamentals of Radionuclides

Part 4 Pharmaceutical Testing, Analysis and Control

30	Analysis of Medicinals	485
31	Biological Testing	540
32	Clinical Analysis	552
33	Chromatography	587
34	Instrumental Methods of Analysis	614
35	Dissolution	654

Part 5 Pharmaceutical Manufacturing

36	Separation
37	Powders
38	Preformulation
39	Solutions, Emulsions, Suspensions, and Extracts
40	Sterilization
11	Parenteral Preparations
12	Intravenous Admixtures
43	Ophthalmic Preparations
44	Medicated Topicals
45	Oral Solid Dosage Forms
46	Coating of Pharmaceutical Dosage Forms
47	Controlled-Release Drug-Delivery Systems
48	The Introduction of New Drugs

10	Biotechnology and Drugs	944
50	Acrosols	963
54	Quality Accuracy and Control	980
51		086
52	Stability of Pharmaceulical Producis	005
53	Bioavailability and Bioequivalency Testing	4005
54	Plastic Packaging Materials	1005
55	Pharmaceutical Necessities	1015

Part 6 Pharmacodynamics

56 57 58 59 60 61 62 63	Diseases: Manifestations and Pathophysiology Drug Absorption, Action, and Disposition Basic Pharmacokinetics Clinical Pharmacokinetics Principles of Immunology Adverse Drug Reactions Pharmacogenetics Pharmacological Aspects of Substance Abuse	1053 1098 1127 1145 1156 1165 1169 1175
	Part 7 Pharmaceutical and Medicinal Agents	
64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83	Diagnostic Drugs and Reagents. Topical Drugs. Gastrointestinal and Liver Drugs. Gastrointestinal and Liver Drugs. Gastrointestinal and Liver Drugs. Cardiovascular Drugs. Respiratory Drugs. Sympathomimetic Drugs. Cholinomimetic Drugs. Adrenergic and Adrenergic Neuron Blocking Drugs. Antimuscarinic and Antispasmodic Drugs. Skeletal Muscle Relaxants. Diuretic Drugs. Uterine and Antimigraine Drugs. Hormones and Hormone Antagonists. General Anesthetics. Local Anesthetics. Sedative and Hypnotic Drugs. Antiepileptic Drugs. Psychopharmacologic Agents. Analgesic, Antipyretic, and Anti-Inflammatory Drugs.	1185 1200 1219 1243 1274 1297 1305 1314 1322 1328 1333 1344 1354 1355 1400 1407 1421 1429 1444 1464
84 85 86 87 88 89	Histamine and Antihistaminic Drugs Central Nervous System Stimulants Antineoplastic and Immunoactive Drugs Anti-Infectives Parasiticides Immunizing Agents and Allergenic Extracts	1404 1471 1477 1507 1562 1567

Part 8 Pharmacy Practice

Part 8A Pharmacy Administration 90 Laws Governing Pharmacy 92 Marketing Pharmaceutical Care Services 93 Documenting and Billing for Pharmaceutical Care 94 Community Pharmacy Economics and 95 Product Recalls and Withdrawals Part 8B Fundamentals of Pharmacy Practice

xiv

97	The Prescription	1687
98	Extemporaneous Prescription Compounding	1706
00	Poison Control	1716
400	Nutrition in Phormacy Practice	1725
100		1738
101	Self-Care/Diagnostic Products	1700
102	Drug Interactions	1/46
103	Complementary and Alternative Medical Health	
	Care	1762
104	Nuclear Pharmacy Practice	1781
105	Enzymes	1792
106		1796
107	Perticides	1825
400	Functional Supplier	1846
100	Surgicul supplies	1957
109	Health Accessories	1057
	AC Deficit Coro	
Part	8C Patient Care	

57. 19.16

1

٠

;

ł

i

ł

Í

1

ļ

ŀ

ţ

ì

Α

DOCKET

R M

110	Ambulatory Patient Care	1893
111	Institutional Patient Care	1911
112	Long-Term Care Facilities	1932

11	3 The Patient: Behavioral Determinants	1948
11		1957
11		1966
11	6 Pharmacoepidemiology	1980
11	7 Integrated Health-Care Delivery Systems	1990
11	B Home Health Patient Care	2012
11	9 Aseptic Technology for Home-Care	2020
	Fightindebildab	
	Appendixes	
		2033
	Periodic Chart	2034

•

Periodic Chart

2036

Glossary and Index

Glossary	2037
Index	2039

xv

Coating of Pharmaceutical Dosage Forms

Stuart C Porter, PhD President PPT Hatfield, PA 19440

Any introduction to tablet coating must be prefaced by an important question—*Why coat tablets*?—since in many instances, the coating is being applied to a dosage form that already is functionally complete. In attempting to answer this question, if one examines the market, it will become apparent that a significant proportion of pharmaceutical solid dosage forms are coated. The reasons for this range from the esthetic to a desire to control the bioavailability of the drug, and include

- 1. Protecting the drug from its surrounding environment (particularly air, moisture, and light) with a view to improving stability.
- 2. Masking of unpleasant taste and odor.
- 3. Increasing the ease by which the product can be ingested by the patient.
- 4. Improving product identity, from the manufacturing plant, through intermediaries, and to the patient.
- 5. Facilitating handling, particularly in high-speed packaging/filling lines, and automated counters in pharmacies, where the coating minimizes cross-contamination due to dust elimination.
- 6. Improving product appearance, particularly where there are noticeable visible differences in tablet core ingredients from batch to batch.
- 7. Reducing the risk of interaction between incompatible components. This would be achieved by using coated forms of one or more of the offending ingredients (particularly active compounds).
- 8. Improving product mechanical integrity, since coated products generally are more resistant to mishandling (abrasion, attrition, etc).
- 9. Modifying drug release, as in enteric-coated, repeat-action and sustained-release products.

EVOLUTION OF THE COATING PROCESS—Tablet coating is perhaps one of the oldest pharmaceutical processes still in existence. Historically, the literature cites Rhazes (850–932 AD) as being one of the earliest *tablet coaters*, having used the mucilage of psyllium seeds to coat pills that had an offending taste. Subsequently, Avicenna¹ was reported to have used gold and silver for pill coating. Since then, there have been many references to the different materials used in *tablet coating*. White² mentioned the use of finely divided talc in what was at one time popularly known as *pearl coating*, while Kremers and Urdang³ described the introduction of the gelatin coating of pills by Garot in 1838.

An interesting reference⁴ reports the use of waxes to coat poison tablets. These waxes, being insoluble in all parts of the gastrointestinal tract, were intended to prevent accidental poisoning (the contents could be utilized by breaking the tablet prior to use).

While earlier coated products were produced by individuals working in pharmacies, particularly when extemporaneous compounding was the order of the day, that responsibility now has been assumed by the pharmaceutical industry. The earliest attempts to apply coatings to pills yielded variable results and usually required the handling of single pills. Such pills would have been mounted on a needle or held with a pair of forceps and literally dipped into the coating fluid, a procedure that would have to be repeated more than once to ensure that the

894

pill was coated completely. Subsequently, the pills were held at the end of a suction tube, dipped, and then the process repeated for the other side of the pill. Not surprisingly, these techniques often failed to produce a uniformly coated product.⁵

Initially, the first sugar-coated pills seen in the US were imported from France about 1842^5 ; while Warner, a Philadelphia pharmacist, became among the first indigenous manufacturers in $1856.^6$

Pharmaceutical pan-coating processes are based on those used in the candy industry, where techniques were highly evolved, even in the Middle Ages. Today most coating pans are fabricated from stainless steel, while early pans were made from copper, because drying was effected by means of an externally applied heat source. Current thinking, even with conventional pans, is to dry the coated tablets with a supply of heated air and remove the moisture and dust-laden air from the vicinity of the pan by means of an air-extraction system.

Pan-coating processes underwent little further change until the late 1940s and early 1950s, with the conventional pan being the mainstay of all coating operations up to that time. However, in the last 30 or 40 years there have been some significant advances made in coating-process technology, mainly as a result of a steady evolution in pan design and its associated ancillary equipment.

Interestingly, in the early years of this development, an entirely new form of technology evolved, that of film coating. Recognizing the deficiencies of the sugar-coating process, advocates of film coating were achieving success by using coating systems involving highly volatile organic solvents.

These solvents circumvented the problems associated with the inefficiency in the drying capabilities of conventional equipment and enabled production quotas to be met with significant reductions in processing times and materials used. The disadvantage of this approach, however, always has been associated with the fact that the solvents used were often flammable and toxic.

The advances that occurred with equipment design, having begun by the development of the Wurster⁷ process and continued by the evolution of side-vented pans, have resulted in the gradual emergence of coating processes in which drying efficiency can be maximized. Thus, film coating began as a process using inefficient drying equipment, relying on highly volatile coating formulations for success, and evolved into one in which the processing equipment is a major factor in ensuring that rapid drying occurs. Improved drying capabilities have permitted common use of aqueous film-coating formulations.

Advances in equipment design also have benefited the sugar-coating process, where, because of current Good Manufacturing Practices (cGMP) and to maintain product uniformity and performance, the trend has been toward using fully automated processes. Nonetheless, film coating tends to dominate as the process of choice for tablet coating.

DOCKET



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

